Evidence map›Paper›PMID 34749809›Full record

ArticleCancer & metabolism2021

Dynamic regulation of mitochondrial pyruvate metabolism is necessary for orthotopic pancreatic tumor growth.

Nancy P Echeverri Ruiz, Vijay Mohan, Jinghai Wu, Sabina Scott, McKenzie Kreamer, Martin Benej, Tereza Golias, Ioanna Papandreou, Nicholas C Denko

Open access · goldAbstract read
In one paragraph

Article in Cancer & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Nancy P Echeverri RuizDepartment of Radiation Oncology, OSUCCC and Wexner Medical Center, The Ohio State University, Columbus, Ohio, 43210, USA.
Vijay MohanDepartment of Radiation Oncology, OSUCCC and Wexner Medical Center, The Ohio State University, Columbus, Ohio, 43210, USA.
Jinghai WuDepartment of Radiation Oncology, OSUCCC and Wexner Medical Center, The Ohio State University, Columbus, Ohio, 43210, USA.
Sabina ScottDepartment of Radiation Oncology, OSUCCC and Wexner Medical Center, The Ohio State University, Columbus, Ohio, 43210, USA.
McKenzie KreamerDepartment of Radiation Oncology, OSUCCC and Wexner Medical Center, The Ohio State University, Columbus, Ohio, 43210, USA.
Martin BenejDepartment of Radiation Oncology, OSUCCC and Wexner Medical Center, The Ohio State University, Columbus, Ohio, 43210, USA.
Tereza GoliasInstitute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, 84505, Slovak Republic.
Ioanna PapandreouDepartment of Radiation Oncology, OSUCCC and Wexner Medical Center, The Ohio State University, Columbus, Ohio, 43210, USA.
Nicholas C DenkoDepartment of Radiation Oncology, OSUCCC and Wexner Medical Center, The Ohio State University, Columbus, Ohio, 43210, USA. nicholas.denko@osumc.edu.ORCID http://orcid.org/0000-0001-6875-734X
The Ohio State University Wexner Medical Center · USBiomedical Research Center of the Slovak Academy of Sciences · SK

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial MetabolismR01CA262388 · NCI · OHIO STATE UNIVERSITY · PI DENKO, NICHOLAS C., LI, ZIHAI · 2021 to 2025
$3.6M
Overcoming hypoxic resistance to anti-cancer therapyR01CA255334 · NCI · OHIO STATE UNIVERSITY · PI DENKO, NICHOLAS C., LI, ZIHAI · 2021 to 2025
$2.9M
Decreasing oxygen metabolism to redcue hypoxia and radiosensitize tumors.R01CA163581 · NCI · OHIO STATE UNIVERSITY · PI DENKO, NICHOLAS C. · 2012 to 2016
$1.7M
Visualizing changes in tumor metabolism using fuctional PET imagingR21CA156950 · NCI · STANFORD UNIVERSITY · PI CHANG, DANIEL T., DENKO, NICHOLAS C. · 2011 to 2012
$464k
NCI NIH HHS P30 CA016058NCI NIH HHS P50CA016058NCI NIH HHS R01 CA163581NCI NIH HHS R01CA163581NCI NIH HHS R01 CA255334NCI NIH HHS R01CA255334NCI NIH HHS R01 CA262388NCI NIH HHS R21 CA156950
6 · The paper itself

Abstract

backgroundPyruvate dehydrogenase complex (PDC) plays a central role in carbohydrate metabolism, linking cytoplasmic glycolysis to the mitochondrial tricarboxylic acid (TCA) cycle. PDC is a conserved E1-E2-E3 dehydrogenase with a PDHA1 and PDHB heterotetramer functioning as the E1 subunit. PDHA1 contains three serine residues that can be reversibly phosphorylated by a dedicated family of four inhibitory pyruvate dehydrogenase kinases (PDHK1-4) and two reactivating phosphatases (PDP1, 2). Hypoxia induces the expression of PDHK1 and PDHK3 and hyperphosphorylates PDHA1. The role of PDC in metabolic reprogramming and tumor progression appears to be for the integration of oncogenic and environmental signals which supports tumor growth.

methodsTo isolate the function of the serine-dependent regulation of PDC, we engineered MiaPaca2 cells to express PDHA1 protein with either intact serines at positions 232, 293, and 300 or all the combinations of non-phosphorylatable alanine substitution mutations. These lines were compared in vitro for biochemical response to hypoxia by western blot, metabolic activity by biochemical assay and Seahorse XF flux analysis, and growth in media with reduced exogenous metabolites. The lines were also tested for growth in vivo after orthotopic injection into the pancreata of immune-deficient mice.

resultsIn this family of cells with non-phosphorylatable PDHA1, we found reduced hypoxic phosphorylation of PDHA1, decreased PDH enzymatic activity in normoxia and hypoxia, decreased mitochondrial function by Seahorse flux assay, reduced in vitro growth of cells in media depleted of lipids, and reduced growth of tumors after orthotopic transplantation of cells into the pancreata of immune-deficient mice.

conclusionsWe found that any substitution of alanine for serine at regulatory sites generated a hypomorphic PDC. However, the reduced PDC activity was insensitive to further reduction in hypoxia. These cells had a very modest reduction of growth in vitro, but failed to grow as tumors indicating that dynamic PDC adaptation to microenvironmental conditions is necessary to support pancreatic cancer growth in vivo.

Indexed as

Glucose metabolismHypoxiaMitochondriaOrthotopic pancreatic tumorsPyruvate dehydrogenase

Identifiers

PMID34749809
PMCPMC8577026
OpenAlexW3195687039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.